Boston, MA 10/02/2013 (wallstreetpr) – Lexicon Pharmaceuticals Incorporation is a biopharmaceutical company that focus on the discovery and development of penetrating treatments of the existent diseases. The company uses an integrated platform of medical technologies and gene knockout technology to analyze the behavioral and psychological functions of almost 5000 genes in mice and assess the utilities of proteins determined by the matching human genes as the target drugs. The company believes in high pharmaceutical value, and engages in programs that lead to the discovery and development of potential new drugs. It has five drug programs which are in various stages of clinical development. The programs are LX1032, LX2931, LX4211, LX7101, and LX1033. The company has also introduced some advanced small molecule compounds from different additional drug programs into various phases of its preclinical research and development. Lexicon is in process of developing the LX4211 program, which is an orally-delivered small molecule compound that can be used to treat diabetes.
According to the Healthcare sector’s update, the health stocks have earned huge revenue on the October 1, 2013. The healthcare sector has added around 0.8% to the Index and all the healthcare companies gained a 0.9% on Oct 1, 2013 in the S&P 500 stock index. The company LXRX has gained by 21% in its trade at $2.89 per share. The company attributes the rise to their declaration of the LX4211 program. It declared that this rise was the highest rise in the past 15 months after the declaration of the program LX4211, in which the company said that the intention behind the formulation of the program was to treat the patients suffering from two types of diabetes, kidney impairment, and will also help meet the primary endpoints in a placebo-control. The company also said that the drug will aim in reducing the glucose level after the patient completes his meal, which is one of the key objectives of diabetes therapy.
